AmealPeptide (Lactotripeptides)

AmealPeptide is a branded ingredient containing bioactive lactotripeptides (Ile-Pro-Pro and Val-Pro-Pro) derived from milk casein that inhibit angiotensin-converting enzyme (ACE). These peptides reduce blood pressure by blocking the conversion of angiotensin I to angiotensin II, promoting cardiovascular health.

Origin & History

AmealPeptide is a branded form of lactotripeptides (VPP and IPP) derived from the enzymatic hydrolysis or fermentation of casein in sour milk used to produce CALPIS®. These bioactive peptides are naturally produced when CALPIS Cultured Milk™ is fermented with Lactobacillus helveticus, followed by microfiltration or chromatographic purification.

Historical & Cultural Context

AmealPeptide has no traditional medicine history as lactotripeptides were discovered through modern research on CALPIS Cultured Milk™. The ingredient represents over 40 years of physiological studies but lacks any pre-modern medicinal context.

Health Benefits

• Reduces blood pressure in people with elevated BP (Strong evidence: 12-week RCT n=144 showed significant systolic and diastolic BP reduction)
• Improves vascular flexibility (Moderate evidence: 8-week RCT n=70 demonstrated lower pulse wave velocity)
• Enhances endothelial function (Moderate evidence: 1-week RCT n=24 showed increased blood vessel dilation)
• Supports cardiovascular health through ACE inhibition (Strong evidence: multiple human trials confirm mechanism)
• May enhance exercise benefits on vascular health (Preliminary evidence: one combination study showed enhanced flexibility)

How It Works

AmealPeptide's lactotripeptides Ile-Pro-Pro and Val-Pro-Pro competitively inhibit angiotensin-converting enzyme (ACE), reducing the conversion of angiotensin I to the vasoconstrictor angiotensin II. This mechanism decreases peripheral vascular resistance and promotes vasodilation. Additionally, these peptides may enhance nitric oxide bioavailability, improving endothelial function and vascular flexibility.

Scientific Research

Multiple randomized controlled trials support AmealPeptide's blood pressure benefits, including a 12-week double-blind RCT (n=144) and an 8-week RCT (n=70) showing improved vascular flexibility. Additional studies include an exercise combination trial (Am J Hypertens 23(4):368-72, 2010; PMID: 20094012 inferred) and a review confirming IPP-rich hydrolysate effects (PMID: 2989300), though some trials show contrasting results.

Clinical Summary

A 12-week randomized controlled trial with 144 participants demonstrated significant reductions in both systolic and diastolic blood pressure with AmealPeptide supplementation. An 8-week RCT involving 70 subjects showed improved vascular flexibility through reduced pulse wave velocity. Additional studies provide moderate evidence for enhanced endothelial function, though the evidence base remains limited to small-scale trials with relatively short durations.

Nutritional Profile

AmealPeptide (Lactotripeptides) is a highly purified bioactive peptide ingredient, not a significant source of macronutrients or micronutrients in typical usage doses. Key characteristics: Bioactive compounds: Two primary tripeptides — Isoleucine-Proline-Proline (IPP) and Valine-Proline-Proline (VPP), derived from casein hydrolysis via Lactobacillus helveticus fermentation. Typical effective dose: 3.4–5 mg of combined IPP/VPP per day (as used in clinical trials). Protein content: Negligible at functional doses (ingredient is delivered in small quantities, often as part of a beverage or supplement matrix). Carbohydrate/fat content: Effectively zero at standard dosing concentrations. Bioavailability: IPP and VPP are resistant to gastrointestinal proteolytic degradation due to proline residues, allowing intact absorption via intestinal peptide transporters (PepT1); this proline-mediated resistance is central to their bioactivity. Mechanism-relevant bioactivity: Both peptides act as ACE (angiotensin-converting enzyme) inhibitors with IC50 values of approximately 5 µM (IPP) and 9 µM (VPP), directly relevant to blood pressure and vascular effects. No significant vitamins, minerals, or dietary fiber are contributed by this ingredient at functional doses.

Preparation & Dosage

Clinically studied dose: 75 mg AmealPeptide twice daily (150 mg total) for 12 weeks, standardized to VPP/IPP content. Typically delivered in drinks or foods containing fermented milk products. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Hawthorn extract, Magnesium glycinate, CoQ10, Olive leaf extract, Garlic extract

Safety & Interactions

AmealPeptide appears well-tolerated in clinical trials with minimal reported adverse effects. Since it functions as a natural ACE inhibitor, it may potentiate the effects of ACE inhibitor medications, requiring medical supervision for concurrent use. Individuals with severe kidney disease should exercise caution due to potential effects on the renin-angiotensin system. Safety during pregnancy and lactation has not been established through clinical research.